Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug tested in liver patients – no cure, just safety check

NCT ID NCT07401862

First seen Feb 14, 2026 · Last updated Apr 30, 2026 · Updated 12 times

Summary

This study looks at how a single shot of eloralintide affects people with mild, moderate, or severe liver damage compared to those with healthy livers. Researchers want to see how the drug moves through the body and if it causes side effects. The study involves 36 adults and lasts about 14 weeks, including a 5-night stay at a clinic. It does not aim to treat or cure liver disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC INSUFFICIENCY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • American Research Corporation

    RECRUITING

    San Antonio, Texas, 78215, United States

    Contact Phone: •••-•••-••••

    Contact

  • CRU Early Phase Unit

    NOT_YET_RECRUITING

    Kistarcsa, H-2143, Hungary

    Contact Phone: •••-•••-••••

    Contact

  • Orlando Clinical Research Center

    RECRUITING

    Orlando, Florida, 32809, United States

    Contact Phone: •••-•••-••••

    Contact

Conditions

Explore the condition pages connected to this study.